Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Radiopharm Theranostics Limited (RADX)

0.8901 -0.1030 (-10.37%)
As of 12:44:26 PM EST. Market Open.
View in AlphaSpace Currency in AUD All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
6/30/2026
6/30/2025
6/30/2024
6/30/2023
Total Revenue
2,767.8880
2,767.8880
3,633.4220
299.2280
292.3590
Cost of Revenue
2,504.4990
2,504.4990
3,594.1460
0
0
Gross Profit
263.3890
263.3890
39.2760
299.2280
292.3590
Operating Expense
58,487.3180
58,487.3180
34,680.0110
37,473.1130
31,982.9600
Operating Income
-58,223.9290
-58,223.9290
-34,640.7350
-37,173.8850
-31,690.6010
Net Non Operating Interest Income Expense
524.7480
524.7480
822.8960
-592.4040
58.9440
Other Income Expense
803.1270
803.1270
-4,421.3260
-10,086.4660
-2,941.5320
Pretax Income
-56,896.0540
-56,896.0540
-38,239.1650
-47,852.7550
-34,573.1890
Tax Provision
54.4400
54.4400
103.2920
96.3640
38.0050
Net Income Common Stockholders
-56,950.4940
-56,950.4940
-38,342.4570
-47,949.1190
-34,611.1940
Diluted NI Available to Com Stockholders
-56,950.4940
-56,950.4940
-38,342.4570
-47,949.1190
-34,611.1940
Basic EPS
-5.37
-5.37
-5.28
-37.23
-32.07
Diluted EPS
-5.37
-5.37
-5.28
-37.23
-32.07
Basic Average Shares
10,244.4800
10,244.4800
6,951.3430
1,288.2000
1,079.3880
Diluted Average Shares
11,814.0540
10,244.4800
6,951.3430
1,288.2000
1,079.3880
Total Operating Income as Reported
-56,783.6580
-56,783.6580
-38,173.8650
-47,209.8670
-34,487.0980
Total Expenses
60,991.8170
60,991.8170
38,274.1570
37,473.1130
31,982.9600
Net Income from Continuing & Discontinued Operation
-56,950.4940
-56,950.4940
-38,342.4570
-47,949.1190
-34,611.1940
Normalized Income
-57,512.6829
-57,512.6829
-35,247.5288
-40,888.5928
-32,552.1216
Interest Income
637.1440
637.1440
888.1960
50.4840
145.0350
Interest Expense
112.3960
112.3960
65.3000
642.8880
86.0910
Net Interest Income
524.7480
524.7480
822.8960
-592.4040
58.9440
EBIT
-56,783.6580
-56,783.6580
-38,173.8650
-47,209.8670
-34,487.0980
EBITDA
-56,776.3270
-56,776.3270
-38,166.5340
-47,202.3330
-34,480.5450
Reconciled Cost of Revenue
2,504.4990
2,504.4990
3,594.1460
0
0
Reconciled Depreciation
7.3310
7.3310
7.3310
7.5340
6.5530
Net Income from Continuing Operation Net Minority Interest
-56,950.4940
-56,950.4940
-38,342.4570
-47,949.1190
-34,611.1940
Total Unusual Items Excluding Goodwill
803.1270
803.1270
-4,421.3260
-10,086.4660
-2,941.5320
Total Unusual Items
803.1270
803.1270
-4,421.3260
-10,086.4660
-2,941.5320
Normalized EBITDA
-57,579.4540
-57,579.4540
-33,745.2080
-37,115.8670
-31,539.0130
Tax Rate for Calcs
0.0003
0.0003
0.0003
0.0003
0.0003
Tax Effect of Unusual Items
240.9381
240.9381
-1,326.3978
-3,025.9398
-882.4596
6/30/2023 - 12/5/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: